MaxCyte IPO Presentation Deck

Cell Therapy Market is Expected to Double Over Next 5 Years across All Approaches and Segments Projected Number of Genetically-modified Cell Therapy Programs (2020-26) Number of Programs July 2021 1,600 1,400 1,200 1,000 800 600 400 200 0 Currently 4 approved therapies -670 2020 ~1,000 2023 Preclinical Clinical Commercial ~1,400 Consistent, substantial market growth, including in the non-viral delivery segment, is expected to increase MaxCyte's addressable opportunity overall Source: DeciBio Cell Therapy Model, Interview Feedback CONFIDENTIAL 2026 13% CAGR 2020-2026 ******* >50 Approved therapies by 2026 …………………………‒‒‒‒‒‒‒‒‒‒‒‒‒‒ >10 Distinct approved indications by 2026 M MaxCyte 28

View entire presentation